Saranas Appoints Mike MacKinnon as CEO

February 27, 2023—Saranas, Inc. announced the appointment of Mike MacKinnon as Chief Executive Officer. Saranas is a privately held medical device company based in Houston, Texas, that is focused on early detection and monitoring of internal bleeding complications.

According to the company, Mr. MacKinnon will accelerate commercialization of Saranas’ Early Bird bleed monitoring system. The device, which is FDA approved for endovascular procedures, is designed to detect bleeds early. The Early Bird system measures changes in bioimpedance to detect and monitor bleeding from vessel injury.

Saranas’ board chairman, Dan Wolterman, stated in the company’s press release, “We are delighted to have Mike join and lead Saranas as we continue our mission establishing early bleed detection and monitoring as the standard of care for patients undergoing endovascular procedures. He is an accomplished executive with an impressive record of bringing disruptive technology to market, guiding strategy, and driving significant growth.”

Mr. MacKinnon added, “I am excited to join Saranas at this important time as the company continues to build commercial momentum and clinical evidence for the Early Bird.”

He continued, “Bleeding remains a common issue during and after endovascular procedures and can result in life-threatening complications. The Early Bird alerts physicians to signs of bleeding in real-time so they can take the necessary actions, protecting patient safety and optimizing clinical outcomes.”

According to the company, Mr. MacKinnon’s 25 years of executive leadership experience include, most recently, serving as a Partner and President of Madison Ventures+, a boutique private equity firm in Greenwood Village, Colorado. Before this, he was CEO of Zidan Medical, an early-stage company focused on endobronchial ablation for early-stage lung cancer, and he was CEO of Rox Medical, a privately held medical device company focused on interventional vascular therapy for uncontrolled hypertension.

For 4 years, Mr. MacKinnon was Vice President, Head of Sales, for Philips North America’s Image-Guided Technologies division. At Philips, he was instrumental in the development and growth of the company’s interventional devices business. He also led the commercial due diligence for the acquisition of Spectranetics in 2017 and integrated a combined 500-person sales team.

He joined Philips after the company’s acquisition of Volcano Corporation, where he served as the General Manager of its Phoenix Atherectomy division and Peripheral Sales Leader. He had joined Volcano as part of the acquisition of AtheroMed in June 2014, which he led as CEO.